Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study of Venetoclax for Subjects Completing Prior Venetoclax Trials
2018-004356-38Phase 3Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and 4 more, sponsored by AbbVie Inc. Primary endpoint: Adverse event collection. Started Aug 2019; status: active.
02
Drugs
venetoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)T-cell prolymphocytic leukemia (T-PLL)chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2018-004356-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004356-38.